New York, February 05, 2015 -- Moody's Investors Service placed Hospira, Inc.'s ratings, including its Ba1 Corporate Family Rating, on review for upgrade. The action follows the announcement that Pfizer Inc. (A1 stable) plans to acquire Hospira for $16 billion in cash plus the assumption of net debt.
Vollständigen Artikel bei Moodys lesen